A High-End Flow Cytometer Breakthrough from Chengdu: PrismTech Tackles the "Bottleneck" Technology for China-Made Substitution

A world premiere is unfolding.

A 4-laser, 20-color flow cytometer independently developed in China has been shipped to Europe, where researchers from the country’s Academy of Sciences are eagerly awaiting the arrival of this precision instrument, labeled “CytoFLUXPro.” Longtime loyal users of international giant BD, they have now chosen to place their trust in a Chinese startup founded just four years ago.

After the device completed experimental demonstrations on-site at the country’s science center, these rigorous scientists were finally convinced. Not long before, under the remote guidance of a client from Xinjiang, the same device was installed within two hours and began sample verification; even earlier, it passed a complex test at an innovative pharmaceutical company in Beijing that domestic industry products had been unable to complete.

In the landscape of China's high-end life science instruments, flow cytometers have long been a field absolutely dominated by multinational giants. International brands such as BD and Beckman, with decades of accumulated technology and brand barriers, occupy over 80% of the market share. Chinese-produced equipment is mostly concentrated in the mid-to-low end, struggling to compete head-on with international products in terms of key performance, stability, and complex applications. The high-end market has always been a "no man's land" that domestically produced instruments find hard to reach.

A technological breakthrough originating from western China is rewriting this pattern.

Located in the Chengdu Economic and Technological Development Zone Incubator Park, Chengdu Prism Tech Biotechnology Co., Ltd. (hereinafter referred to as "Prism Tech") has, in just a few years, made the leap from core optical technology breakthroughs to the commercialization of high-end products with a challenger's attitude. Its self-developed three-laser, four-laser, and even five-laser flow cytometers not only rival international top-tier products in key parameters such as multi-color detection capabilities (up to 30 colors), optical resolution, and sensitivity, but also successfully entered China’s top-tier tertiary hospitals and leading innovative pharmaceutical companies with excellent stability and customer-oriented rapid iteration capabilities, while also being exported to high-end markets in Europe and the Middle East.

Recently, VCBeat conducted an exclusive interview with Fu Zhiyong, founder and general manager of Prismatech, delving into how this company has achieved a remarkable transformation from "follower" to "leader" in the high-end precision instrument sector—a hardcore technology track—through its unique methodology of "technology as the foundation, customer-driven, and quality as the core." This is not only a growth narrative of an enterprise but also a window into observing how China's high-end manufacturing industry builds global competitiveness and reshapes the industrial landscape.

The founding of PrismTek stems from the founder's insight into industry trends and a pivotal path decision. Fu Zhiyong, the founder, worked for many years in GE Corporate’s global team, where he was responsible for auditing and frequently engaged with top consulting firms’ industry reports, which made him acutely aware of the central role of flow cytometry in the life sciences field. During the COVID-19 pandemic in 2020, the application of flow cytometry technology in cytokine detection further solidified his determination to start his own business.

After joining forces with classmates who had an optics background from MIT, the team broke down the flow cytometer into three core modules: optics, fluidics, and software, establishing the攻坚principle of "optics first." "If we can't get the optical system right, nothing else matters," recalled Fu Zhiyong. After nearly a year and a half of difficult exploration, the team successfully突破key optical technology by the end of 2021.

More crucially, in terms of technology roadmap selection, PrismTek did not follow the APD (Avalanche Photodiode) route commonly adopted by mainstream domestic manufacturers. Instead, it resolutely chose the same PMT (Photomultiplier Tube) technology route as BD. "Our positioning has been to develop high-end equipment from the very beginning, with the goal of being able to compete head-on with BD and Beckman's high-end devices," emphasized Fu Zhiyong.

This choice, while implying a higher technical threshold and initial investment, has laid a foundation of high performance and high reliability for the product, and paved the way for subsequent entry into the high-end market.Based on this, PrismTech has achieved the first independent application of all-fiber optic technology in flow cytometry in China.Its self-developed three-laser flow cytometer has been awarded the title of "Sichuan Province Innovative Medical Device," and its flow sperm analyzer has also been recognized as a "First-of-its-kind Major Technical Equipment Product in Sichuan Province," with its technical capabilities officially certified.

If the technical route is the "skeleton" of Prismatech, then the product philosophy of "customer-guided R&D" is its vibrant "blood" and "nerves." This sets it apart from many technology-driven companies that develop products in isolation.

The company's first product, EVA (a two-laser, six-color flow cytometer), obtained a medical device registration certificate in early 2023. However, Fu Zhiyong made an unconventional decision: to withhold the product from sale, instead deploying it in real-world "stress tests" and extensive refinement for over a year at the National Key Laboratory of West China, Sichuan Provincial People's Hospital, and several leading biopharmaceutical enterprises.

PrismTek Full Series of Flow Products: Utilizing new fiber optic and lens technology, no optical path adjustment required; ready to use upon startup, no warm-up waiting time; portable, long-distance transportation does not affect detection accuracy; unique fluid cleaning system prevents contamination and clogging; patented bubble removal and impurity elimination technology ensures purer data.

One of the leading innovative pharmaceutical companies, ConnaMed, played a crucial "co-creation partner" role in this process, providing 188 detailed improvement suggestions covering hardware, software, and operational procedures. The R&D team of PrismTech demonstrated remarkable agility and execution capability, completing all improvements within just 87 days, which also gave rise to multiple new technology patents. "What truly drives the company's growth are the users. Their needs listed one by one in Excel sheets are our most valuable assets," Fu Zhiyong admitted frankly.

This model of deep binding with top users enables Prismatech to precisely address industry pain points. For instance, in response to the long-standing issue of fluid pathway blockages frequently complained about by clinical users, the company developed a unique anti-clogging design; to meet the high-throughput drug screening needs of pharmaceutical enterprises, they developedOne-click high-throughput data analysis module shortens the original weeks of manual data analysis work to two hours.The company's product decisions also strictly follow market logic. It once decisively halted the "imaging flow cytometry" project, which had a very small market capacity, and instead concentrated resources on developing multi-laser flow systems with clear market demand, ensuring the efficient conversion of R&D investment.

The company's first product, EVA (two lasers, six colors), was a trial product, and it now covers nearly 30 customers with extremely high stability. However, the more important products are the CytoFLUX series—high-end equipment such as three lasers with 15 colors and four lasers with 25 colors. These are the main products through which PrismTek competes with international giants.

The company launched sales in April 2024, sold the first unit in September, and has sold more than 100 units to date, with performance growing tenfold in a year. Behind this growth rate lies Prismatech's relentless pursuit of product quality.

In addition, the company has also established a unique "R&D responsible for after-sales" model to ensure that the technical team always stays close to user needs. R&D personnel are not only responsible for product development but also personally handle equipment installation and communicate with customers. This mechanism makes product iteration more market-oriented. It is precisely through a profound understanding of real needs and rapid response that Prismatech has not only launchedThe world's first flow sperm analyzer, together with a dedicated flow sample pre-processing system, integrates automation and intelligence into the workflow, continuously setting new industry standards.

In the primary market atmosphere that generally pursues growth speed and scale, Prismatech exhibits a "consensus-disrupting" determination based on its manufacturing heritage. Fu Zhiyong has embedded precise manufacturing management systems, such as Six Sigma accumulated from multinational enterprises, into the company's DNA, demonstrating an almost obsessive pursuit of quality.

In terms of cost control, the company has set a clear red line: no cost-reduction optimization at the expense of reliability will be carried out until the cumulative shipments of the product reach 500 units. "Blind cost-cutting in the early stage leads to an increase in failure rates and surging after-sales costs, which is a trap that swallows many companies. We prioritize building reputation and scale, and the supply chain costs will naturally optimize," explained Fu Zhiyong. The company’s procurement standards for core components are extremely strict, requiring suppliers to be among the top three in the Chinese market or the top ten globally, ensuring the 'high-end' essence of the products from the source. In fact, the equipment independently developed by the company not only rivals international first-tier products in performance,Compared with imported products,Cost reduced by 40%, with annual maintenance costs significantly lower than imported equipment.

Based on strong product capabilities, Prismatech's global expansion strategy is clear and efficient, and tailored to local conditions——

High-End Market Battle: In markets such as Europe and the United States, focus on promoting high-end models with three or more lasers, directly competing with international giants for top research institutions and pharmaceutical enterprise clients.

Customization for Emerging Markets: Develop cost-effective HIV testing equipment tailored to public health needs in Southeast Asia; provide top-tier configuration solutions for the Middle East market with its preference for "high-end brands."

Principle of Localized Channels: The company adheres to direct cooperation with local agents in overseas markets, eliminating intermediaries to ensure the accuracy of market insights and the depth of services, thereby building a stable overseas channel network.

PrismTech Products Installed Overseas

The above strategy ensures a long-term stable cooperative relationship. The equipment of Prismatech has gained recognition in the European market, thanks not only to its technical strength but also to its industrial design that conforms to European aesthetics and its simple operation interface. In addition, all agents must purchase sample machines to provide trial experiences for customers. "For a new brand, no matter how advanced the technical parameters are, customers won't easily believe it. Only by letting them experience it practically can they have a say," said Fu Zhiyong.

Prismatek products installed overseas

In 2026, PrismTech enters a critical acceleration phase of development. In terms of product lines, a new model of "nano-flow cytometry" for the detection of exosomes and other nanoparticles will soon be released, further expanding technological boundaries. Meanwhile, the company is actively advancing the application for multiple Class III and Class II medical device registration certificates, paving the way for large-scale expansion in the clinical market.

In Fu Zhiyong's plan,PrismTek's positioning goes beyond being a mere medical device company. "Flow cytometry is essentially a particle detection platform. We are a high-end scientific instrument company, and our future applications can extend to broader industrial and scientific research fields."

In addition, the company is systematically conducting market education and ecosystem cultivation through professional content platforms such as the "Flow Cytometry Ecosystem," attracting and nurturing the next generation of users.

In terms of financing planning, Prismtek, a company that has developed solely依靠自有资金发展至今, is about to launch its first round of financing. "We need capital to accelerate corporate growth, expand production capacity, and support ongoing R&D," said Fu Zhiyong. He has clear expectations for potential investors: they must not only provide funding but also demonstrate patience and foresight, understanding the development patterns of high-end manufacturing. With the expansion of production scale and the initiation of a new financing round, Prismtek is transitioning from a technological dark horse to an industry leader with continuous innovation, large-scale delivery capabilities, and global brand influence.

The story of PrismTek is one about strategic determination, product belief, and global ambition. It demonstrates that in the high-tech barrier field of advanced scientific instruments, Chinese companies are not limited to low-price followers. By choosing the right technological path, establishing a user-centered innovation loop, and adhering to the quality philosophy of manufacturing, they can also break through obstacles and win the trust of the most demanding customers both domestically and internationally.

Fu Zhiyong views the company's location in Chengdu as a form of "isolated protection," shielding it from the restless environment of homogenized competition and allowing it to focus on refining its products. Today, starting from Chengdu, Prismatech's products have been sold worldwide. Its experience demonstrates that the rise of China's high-end manufacturing requires not only capital and policy but also the long-term patient dedication deeply rooted in products and customers.